Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Peter Hecht Biography and Net Worth

CEO of Cyclerion Therapeutics

Dr. Hecht served as the co-founder and chief executive officer of Ironwood Pharmaceuticals from 1998 to 2019. Under his leadership, Ironwood grew from nine Ph.D. scientists to a commercial biotechnology company that discovered, developed and is now commercializing LINZESS^® – the branded prescription market leader in its class. Additionally, during his tenure the company pioneered new areas of science, delivered a promising development portfolio with multiple innovative drug candidates and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. He also served on the Ironwood board from 1998 to 2019, and currently serves on the board of Kallyope Inc., a privately held biotechnology company.  Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht earned a B.S. in mathematics and an M.S. in biology from Stanford University, and a Ph.D. in molecular biology from the University of California at Berkeley.

What is Peter M. Hecht's net worth?: The estimated net worth of Peter M. Hecht is at least $283,603.68 as of June 3rd, 2021. Dr. Hecht owns 102,384 shares of Cyclerion Therapeutics stock worth more than $283,604 as of April 24th. This net worth estimate does not reflect any other investments that Dr. Hecht may own. Learn More about Peter M. Hecht's net worth.
How do I contact Peter M. Hecht?: The corporate mailing address for Dr. Hecht and other Cyclerion Therapeutics executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Cyclerion Therapeutics can also be reached via phone at (857) 327-8778 and via email at [email protected]. Learn More on Peter M. Hecht's contact information.
Has Peter M. Hecht been buying or selling shares of Cyclerion Therapeutics?: Peter M. Hecht has not been actively trading shares of Cyclerion Therapeutics during the past quarter. Most recently, on Thursday, June 3rd, Peter M. Hecht bought 41,158 shares of Cyclerion Therapeutics stock. The stock was acquired at an average cost of $65.60 per share, with a total value of $2,699,964.80. Following the completion of the transaction, the chief executive officer now directly owns 102,384 shares of the company's stock, valued at $6,716,390.40. Learn More on Peter M. Hecht's trading history.
Who are Cyclerion Therapeutics' active insiders?: Cyclerion Therapeutics' insider roster includes Peter Hecht (CEO), and Terrance Mcguire (Director). Learn More on Cyclerion Therapeutics' active insiders.
Are insiders buying or selling shares of Cyclerion Therapeutics?: In the last twelve months, insiders at the sold shares 1 times. They sold a total of 8 shares worth more than $27.20. The most recent insider tranaction occured on August, 9th when Director Terrance Mcguire sold 8 shares worth more than $27.20. Insiders at Cyclerion Therapeutics own 13.1% of the company. Learn More about insider trades at Cyclerion Therapeutics.
Information on this page was last updated on 8/9/2023.

Peter M. Hecht Insider Trading History at Cyclerion Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2021	Buy	41,158	$65.60	$2,699,964.80	102,384
5/6/2021	Buy	15,100	$48.60	$733,860.00	61,226
5/4/2021	Buy	15,000	$45.80	$687,000.00	26,226

Peter M. Hecht Buying and Selling Activity at Cyclerion Therapeutics

Cyclerion Therapeutics Company Overview

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.77

$2.77

50 Day Range

MA: $3.10

$2.77

$3.50

2 Week Range

Now: $2.77

$1.75

$6.75

Volume

669 shs

Average Volume

3,210 shs

Market Capitalization

$7.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84